•
Jun 30, 2024

SIGA Technologies Q2 2024 Earnings Report

SIGA Technologies' Q2 2024 financial performance was marked by revenue generation and strategic advancement.

Key Takeaways

SIGA Technologies reported a strong second quarter in 2024, with total revenues of $21.8 million, driven by product sales of $20.7 million. The company achieved a net income of $1.8 million, resulting in a diluted income per share of $0.03. Additionally, SIGA received a $113 million procurement order from the U.S. Government for oral TPOXX in July.

Generated $21 million in total revenues, with $20.7 million from product sales.

Achieved net income of $1.8 million, resulting in diluted earnings per share of $0.03.

Received a $113 million procurement order from the U.S. Government for oral TPOXX in July.

Delivered $18 million of IV TPOXX to the U.S. SNS and $3 million of oral TPOXX to a new customer in the ASEAN region during Q2 2024.

Total Revenue
$21.8M
Previous year: $5.88M
+271.1%
EPS
$0.03
Previous year: -$0.04
-175.0%
Gross Profit
$9.5M
Previous year: -$212K
-4572.2%
Cash and Equivalents
$107M
Previous year: $76.2M
+40.3%
Free Cash Flow
$5.95M
Total Assets
$193M
Previous year: $147M
+31.5%

SIGA Technologies

SIGA Technologies

SIGA Technologies Revenue by Segment

Forward Guidance

SIGA Technologies is focused on diversifying and expanding its revenue base, progressing its clinical programs, negotiating the next contract with the U.S. Government, and promoting public health.

Revenue & Expenses

Visualization of income flow from segment revenue to net income